You have read all your free articles, to continue reading subscribe to read the rest of this content.
Spago Nanomedical has received regulatory approval to initiate a Phase IIa clinical study with its MRI contrast agent SN132D in endometriosis. Patient recruitment has started, and the first patient is expected to be dosed shortly. The ongoing SPAGOPIX-01 study in breast cancer has now been concluAlready a subscriber Login You…
Saniona, a biotech company in the field of ion channels, has announced that the University of Pennsylvania Treatment Research Center (TRC) has initiated recruitment of patients in a Phase 2a study for their compound, NS2359, for treatment of cocaine addiction. Today there are no approved drugs Already a subscriber Login You have…
Results from the OSTRO Phase III trial showed AstraZeneca’s Fasenra (benralizumab) compared with placebo demonstrated a statistically significant improvement in the size of nasal polyps and in nasal blockage in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Fasenra demonstratAlready a subscriber Login You have read all your free articles, to…
AstraZeneca and MSD have announced positive results from the Phase III POLO trial. Results from the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with Lynparza (olaparib) vs. placebo. The safety and tolerability profile of LynAlready a subscriber Login You have read all your free articles, to continue reading subscribe…
